Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasal Delivery of hDFSCs-Exo for Negative Symptoms in Treatment-Resistant Schizophrenia
NCT07485751Phase 1Not yet recruiting
- Sponsor
- Zigong Mental Health Center
- Start
- Mar 2026
- Primary completion
- Sep 2026
- Modality
- Lipid-based Nanoparticles
01
Overview
Phase 1, open-label, single-arm trial of hDFSCs-Exo in schizophrenia, sponsored by Zigong Mental Health Center. Primary endpoints: Incidence and severity of adverse events and serious adverse events at 24 weeks, Dose-limiting toxicity at 28 days and 3 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
hDFSCs-Exo
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07485751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07485751.